Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

While MS isn’t fatal on its own, accompanying complications can shorten life. That said, treatment can significantly decrease the chance of a shortened life span. When it comes to the outlook ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

Many people who receive an initial diagnosis of relapsing-remitting MS gradually worsen over time, separate from ...

Decades of subtle health changes went by without answers. When worsening disability led Roger to a multiple sclerosis (MS) ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance. The change of heart ...

The company is testing a fully human anti-CD3 monoclonal antibody, foralumab, in secondary progressive multiple sclerosis [SPMS] and Alzheimer’s disease [AD]. Trial results from a randomized ...